Blocking extracellular Galectin-3 in patients with osteoarthritis

This pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering from knee osteoarthritis (OA). 50 patients were randomized in a 1:1 ratio to receive MCP or placebo at a dose of 4 g (5 capsules) twice daily for 12 w...

Full description

Saved in:

Bibliographic Details
Published in:	Contemporary clinical trials communications Vol. 17; p. 100500
Main Authors:	Andrews, Alec R., Fernandes, Ana D., Brownmiller, Seth E., Hanna, Yousif, Fisher, Mark C., Huang, Christene A.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Inc 01-03-2020 Elsevier
Subjects:	Galectin-3 Modified citrus pectin Osteoarthritis OA Galectin-3 MCP Osteoarthritis Modified citrus pectin Gal-3 MCP, Modified Citrus Pectin OA, Osteoarthritis Gal-3, Galectin-3
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	This pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering from knee osteoarthritis (OA). 50 patients were randomized in a 1:1 ratio to receive MCP or placebo at a dose of 4 g (5 capsules) twice daily for 12 weeks. Serum Gal-3 levels and OA severity were evaluated at baseline and 12 weeks. Gal-3 levels were detected by sandwich ELISA and OA severity was determined using WOMAC-knee, SF-36, and RAPID3 surveys during these visits. MCP tolerability was assessed by a basic metabolic panel during a week 6 follow up visit. Patients enrolled in both the MCP treatment and placebo groups shared similar baseline characteristics in OA severity, serum Gal-3 levels, and pain management. Improvement across all surveys was noted independent of supplement or placebo treatment. No significant change in Gal-3 levels were observed in either cohort over the 12-week study. Treatment of knee OA with a 12-week course of MCP did not significantly improve disease burden compared to placebo.
AbstractList	This pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering from knee osteoarthritis (OA). 50 patients were randomized in a 1:1 ratio to receive MCP or placebo at a dose of 4 g (5 capsules) twice daily for 12 weeks. Serum Gal-3 levels and OA severity were evaluated at baseline and 12 weeks. Gal-3 levels were detected by sandwich ELISA and OA severity was determined using WOMAC-knee, SF-36, and RAPID3 surveys during these visits. MCP tolerability was assessed by a basic metabolic panel during a week 6 follow up visit. Patients enrolled in both the MCP treatment and placebo groups shared similar baseline characteristics in OA severity, serum Gal-3 levels, and pain management. Improvement across all surveys was noted independent of supplement or placebo treatment. No significant change in Gal-3 levels were observed in either cohort over the 12-week study. Treatment of knee OA with a 12-week course of MCP did not significantly improve disease burden compared to placebo. Objective: This pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering from knee osteoarthritis (OA). Methods: 50 patients were randomized in a 1:1 ratio to receive MCP or placebo at a dose of 4 g (5 capsules) twice daily for 12 weeks. Serum Gal-3 levels and OA severity were evaluated at baseline and 12 weeks. Gal-3 levels were detected by sandwich ELISA and OA severity was determined using WOMAC-knee, SF-36, and RAPID3 surveys during these visits. MCP tolerability was assessed by a basic metabolic panel during a week 6 follow up visit. Results: Patients enrolled in both the MCP treatment and placebo groups shared similar baseline characteristics in OA severity, serum Gal-3 levels, and pain management. Improvement across all surveys was noted independent of supplement or placebo treatment. No significant change in Gal-3 levels were observed in either cohort over the 12-week study. Conclusion: Treatment of knee OA with a 12-week course of MCP did not significantly improve disease burden compared to placebo. Keywords: Osteoarthritis, Galectin-3, Modified citrus pectin OBJECTIVEThis pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering from knee osteoarthritis (OA). METHODS50 patients were randomized in a 1:1 ratio to receive MCP or placebo at a dose of 4 g (5 capsules) twice daily for 12 weeks. Serum Gal-3 levels and OA severity were evaluated at baseline and 12 weeks. Gal-3 levels were detected by sandwich ELISA and OA severity was determined using WOMAC-knee, SF-36, and RAPID3 surveys during these visits. MCP tolerability was assessed by a basic metabolic panel during a week 6 follow up visit. RESULTSPatients enrolled in both the MCP treatment and placebo groups shared similar baseline characteristics in OA severity, serum Gal-3 levels, and pain management. Improvement across all surveys was noted independent of supplement or placebo treatment. No significant change in Gal-3 levels were observed in either cohort over the 12-week study. CONCLUSIONTreatment of knee OA with a 12-week course of MCP did not significantly improve disease burden compared to placebo.
ArticleNumber	100500
Author	Huang, Christene A. Brownmiller, Seth E. Andrews, Alec R. Hanna, Yousif Fernandes, Ana D. Fisher, Mark C.
AuthorAffiliation	b Department of Rheumatology, Massachusetts General Hospital, Boston, MA, USA a Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA c Department of Surgery, Division of Plastic and Reconstructive Surgery, Division of Transplant Surgery, University of Colorado School of Medicine, Aurora, CO, USA
AuthorAffiliation_xml	– name: b Department of Rheumatology, Massachusetts General Hospital, Boston, MA, USA – name: a Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA – name: c Department of Surgery, Division of Plastic and Reconstructive Surgery, Division of Transplant Surgery, University of Colorado School of Medicine, Aurora, CO, USA
Author_xml	– sequence: 1 givenname: Alec R. surname: Andrews fullname: Andrews, Alec R. organization: Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA – sequence: 2 givenname: Ana D. surname: Fernandes fullname: Fernandes, Ana D. organization: Department of Rheumatology, Massachusetts General Hospital, Boston, MA, USA – sequence: 3 givenname: Seth E. surname: Brownmiller fullname: Brownmiller, Seth E. organization: Department of Rheumatology, Massachusetts General Hospital, Boston, MA, USA – sequence: 4 givenname: Yousif orcidid: 0000-0002-5346-2124 surname: Hanna fullname: Hanna, Yousif organization: Department of Rheumatology, Massachusetts General Hospital, Boston, MA, USA – sequence: 5 givenname: Mark C. surname: Fisher fullname: Fisher, Mark C. organization: Department of Rheumatology, Massachusetts General Hospital, Boston, MA, USA – sequence: 6 givenname: Christene A. surname: Huang fullname: Huang, Christene A. email: christene.huang@ucdenver.edu, christene.huang@cuanschutz.edu organization: Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31872160$$D View this record in MEDLINE/PubMed
BookMark	eNp9kU1vEzEQhi1UREvoP0Boj1w2-Gv9cUEqFZRKlbjA2XJmZxOHzTrYTgv_Hoctpb1wsjUf7zszz0tyMsUJCXnN6JJRpt5tlxAnKLDklNkaoh2lz8gZlx1rjerkyaP_KTnPeUtp7ROa8e4FORXMaM4UPSMXH8YI38O0bvBnSR5wHA-jT82VHxFKmFrRhKnZ-xJwKrm5C2XTxFww-lQ2KZSQX5Hngx8znt-_C_Lt08evl5_bmy9X15cXNy103JaWadMPbJBKdrKXg9BGKG4VHVYrr0H3VCumOi6tRm-BSkA7sForDEMEr8SCXM-6ffRbt09h59MvF31wfwIxrV2dKcCIDgbTg_CsNxqkldLQamipMp4hp1VzQd7PWvvDaoc91N2SH5-IPs1MYePW8dYpSy3nR4G39wIp_jhgLm4X8vF4fsJ4yI4LQYUQUvJaKudSSDHnhMODDaPuCNNt3QzTHWG6GWZte_N4xIemv-j-7YD16LcBk8tQIQH2IVV09Srh_w6_AV4YsyM
CitedBy_id	crossref_primary_10_1016_j_clinbiochem_2023_02_011 crossref_primary_10_3390_ijerph191811480 crossref_primary_10_1016_j_biomaterials_2022_121870 crossref_primary_10_1016_j_ijbiomac_2023_128594
Cites_doi	10.1038/nrrheum.2016.136 10.1038/nrrheum.2010.159 10.1161/01.CIR.0000147181.65298.4D 10.12659/MSM.903472 10.1111/j.1600-065X.2009.00794.x 10.1136/ard.2006.067470 10.1177/1177271918771969 10.1097/01.bor.0000129663.76107.d6 10.1002/art.11287 10.1177/1759720X12467868 10.1016/j.joca.2014.01.003 10.1080/AC.70.3.3080637 10.1136/rmdopen-2018-000715 10.1371/journal.pone.0018683 10.1016/j.joca.2018.10.014
ContentType	Journal Article
Copyright	2019 The Authors 2019 The Authors. Published by Elsevier Inc. 2019 The Authors. Published by Elsevier Inc. 2019
Copyright_xml	– notice: 2019 The Authors – notice: 2019 The Authors. Published by Elsevier Inc. – notice: 2019 The Authors. Published by Elsevier Inc. 2019
DBID	6I. AAFTH NPM AAYXX CITATION 7X8 5PM DOA
DOI	10.1016/j.conctc.2019.100500
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals
DatabaseTitle	PubMed CrossRef MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic PubMed
Database_xml	– sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	2451-8654
EndPage	100500
ExternalDocumentID	oai_doaj_org_article_cf8dc3a1d87c4944804f39068a1e2054 10_1016_j_conctc_2019_100500 31872160 S2451865419302637
Genre	Journal Article
GroupedDBID	.1- .FO 0R~ 0SF 1P~ 457 53G 6I. AACTN AAEDW AAFTH AALRI AAXUO ABMAC ACGFS ADBBV ADEZE AEVXI AEXQZ AFCTW AFRHN AFTJW AGHFR AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BCNDV EBS EJD FDB GROUPED_DOAJ HYE KQ8 M~E NCXOZ O9- OK1 ROL RPM SSZ Z5R ADVLN AFJKZ NPM AAYXX CITATION 7X8 5PM
ID	FETCH-LOGICAL-c529t-178df1f46454d4f378362960fbba7c7d0761652497ea9c04ce9f1454381eeca63
IEDL.DBID	RPM
ISSN	2451-8654
IngestDate	Tue Oct 22 15:16:23 EDT 2024 Tue Sep 17 21:17:54 EDT 2024 Sat Oct 26 00:01:13 EDT 2024 Thu Sep 26 17:47:34 EDT 2024 Sat Sep 28 08:21:19 EDT 2024 Tue Jul 25 21:02:36 EDT 2023
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Keywords	OA Galectin-3 MCP Osteoarthritis Modified citrus pectin Gal-3 MCP, Modified Citrus Pectin OA, Osteoarthritis Gal-3, Galectin-3
Language	English
License	This is an open access article under the CC BY-NC-ND license. 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c529t-178df1f46454d4f378362960fbba7c7d0761652497ea9c04ce9f1454381eeca63
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Denotes that these authors contributed equally to this work.
ORCID	0000-0002-5346-2124
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909224/
PMID	31872160
PQID	2330333442
PQPubID	23479
PageCount	1
ParticipantIDs	doaj_primary_oai_doaj_org_article_cf8dc3a1d87c4944804f39068a1e2054 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6909224 proquest_miscellaneous_2330333442 crossref_primary_10_1016_j_conctc_2019_100500 pubmed_primary_31872160 elsevier_sciencedirect_doi_10_1016_j_conctc_2019_100500
PublicationCentury	2000
PublicationDate	2020-03-01
PublicationDateYYYYMMDD	2020-03-01
PublicationDate_xml	– month: 03 year: 2020 text: 2020-03-01 day: 01
PublicationDecade	2020
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	Contemporary clinical trials communications
PublicationTitleAlternate	Contemp Clin Trials Commun
PublicationYear	2020
Publisher	Elsevier Inc Elsevier
Publisher_xml	– name: Elsevier Inc – name: Elsevier
References	Sokolove, Lepus (bib5) 2013; 5 Sharma, Pokharel, van Brakel (bib7) 2004; 110 Kolatsi-Joannou, Price, Winyard, Long (bib12) 2011; 6 Mosleh, Chaudhari, Sonkawade (bib16) 2018; 13 Mineten, Blom, Snijders (bib2) 2019; 27 McAlindon, Bannuru, Sullivan (bib6) 2014; 22 Feng, Wu, Li (bib15) 2017; 23 Reboul, Martel-Pelletier, Pelletier (bib11) 2004; 16 Thijssen, Heusschen, Caers, Griffioen (bib10) 2015; 1855 Lundgren-Nilsson, Dencker, Palstam (bib13) 2018; 4 Robinson, Lepus, Wang (bib3) 2016; 12 Hill, Hunter, Niu (bib1) 2007; 66 Henderson, Sethi (bib9) 2009; 230 Ohshima, Kuchen, Seemayer (bib14) 2003; 48 Sellam, Berenbaum (bib4) 2010; 6 Lala, Puschita, Darabantiu, Pilat (bib8) 2015; 70 Sellam (10.1016/j.conctc.2019.100500_bib4) 2010; 6 Reboul (10.1016/j.conctc.2019.100500_bib11) 2004; 16 Mosleh (10.1016/j.conctc.2019.100500_bib16) 2018; 13 Hill (10.1016/j.conctc.2019.100500_bib1) 2007; 66 Sharma (10.1016/j.conctc.2019.100500_bib7) 2004; 110 Ohshima (10.1016/j.conctc.2019.100500_bib14) 2003; 48 McAlindon (10.1016/j.conctc.2019.100500_bib6) 2014; 22 Henderson (10.1016/j.conctc.2019.100500_bib9) 2009; 230 Feng (10.1016/j.conctc.2019.100500_bib15) 2017; 23 Lala (10.1016/j.conctc.2019.100500_bib8) 2015; 70 Thijssen (10.1016/j.conctc.2019.100500_bib10) 2015; 1855 Mineten (10.1016/j.conctc.2019.100500_bib2) 2019; 27 Kolatsi-Joannou (10.1016/j.conctc.2019.100500_bib12) 2011; 6 Robinson (10.1016/j.conctc.2019.100500_bib3) 2016; 12 Sokolove (10.1016/j.conctc.2019.100500_bib5) 2013; 5 Lundgren-Nilsson (10.1016/j.conctc.2019.100500_bib13) 2018; 4
References_xml	– volume: 5 start-page: 77 year: 2013 end-page: 94 ident: bib5 article-title: Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations publication-title: Ther Adv Musculoskelet Dis contributor: fullname: Lepus – volume: 12 start-page: 580 year: 2016 end-page: 592 ident: bib3 article-title: Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis publication-title: Nat. Rev. Rheumatol. contributor: fullname: Wang – volume: 230 start-page: 160 year: 2009 end-page: 171 ident: bib9 article-title: The regulation of inflammation by galectin-3 publication-title: Immunol. Rev. contributor: fullname: Sethi – volume: 48 start-page: 2788 year: 2003 end-page: 2795 ident: bib14 article-title: Galectin 3 and its binding protein in rheumatoid arthritis publication-title: Arthritis Rheum. contributor: fullname: Seemayer – volume: 110 start-page: 3121 year: 2004 end-page: 3128 ident: bib7 article-title: Galectin-3 marks activated macrophages in failure-prone hypertophied hearts and contributes to cardiac dysfunction publication-title: Circulation contributor: fullname: van Brakel – volume: 6 year: 2011 ident: bib12 article-title: Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury publication-title: PLoS One contributor: fullname: Long – volume: 6 start-page: 625 year: 2010 end-page: 635 ident: bib4 article-title: The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis publication-title: Nat. Rev. Rheumatol. contributor: fullname: Berenbaum – volume: 23 start-page: 4612 year: 2017 end-page: 4618 ident: bib15 article-title: Association of serum galectin-3 with acute exacerbation of chronic obstructive pulmonary disease publication-title: Med. Sci. Monit. contributor: fullname: Li – volume: 70 start-page: 323 year: 2015 end-page: 331 ident: bib8 article-title: Galectin-3 in heart failure pathology--"another brick in the wall"? publication-title: Acta Cardiol. contributor: fullname: Pilat – volume: 16 start-page: 595 year: 2004 end-page: 598 ident: bib11 article-title: Galectin-3 in osteoarthritis: when the fountain of youth doesn't deliver its promises publication-title: Curr. Opin. Rheumatol. contributor: fullname: Pelletier – volume: 22 start-page: 363 year: 2014 end-page: 388 ident: bib6 article-title: OARSI guidelines for the non-surgical management of knee osteoarthritis publication-title: Osteoarthr. Cartil. contributor: fullname: Sullivan – volume: 27 start-page: 71 year: 2019 end-page: 79 ident: bib2 article-title: Exploring longitudinal associations of histologically assessed inflammation with symptoms and radiographic damage in knee osteoarthritis: combined results of three prospective cohort studies publication-title: Osteoarthr. Cartil. contributor: fullname: Snijders – volume: 13 year: 2018 ident: bib16 article-title: The therapeutic potential of blocking galectin-3 expression in acute myocardial infarction and mitigating inflammation of infarct region: a clinical outcome-based translational study publication-title: Biomark. Insights contributor: fullname: Sonkawade – volume: 1855 start-page: 235 year: 2015 end-page: 247 ident: bib10 article-title: Galectin expression in cancer diagnosis and prognosis: a systematic review publication-title: Biochim. Biophys. Acta contributor: fullname: Griffioen – volume: 4 year: 2018 ident: bib13 article-title: Patient-reported outcome measures in osteoarthritis: a systematic search and review of their use and psychometric properties publication-title: RMD Open contributor: fullname: Palstam – volume: 66 start-page: 1599 year: 2007 end-page: 1603 ident: bib1 article-title: Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis publication-title: Ann. Rheum. Dis. contributor: fullname: Niu – volume: 12 start-page: 580 year: 2016 ident: 10.1016/j.conctc.2019.100500_bib3 article-title: Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis publication-title: Nat. Rev. Rheumatol. doi: 10.1038/nrrheum.2016.136 contributor: fullname: Robinson – volume: 6 start-page: 625 year: 2010 ident: 10.1016/j.conctc.2019.100500_bib4 article-title: The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis publication-title: Nat. Rev. Rheumatol. doi: 10.1038/nrrheum.2010.159 contributor: fullname: Sellam – volume: 110 start-page: 3121 year: 2004 ident: 10.1016/j.conctc.2019.100500_bib7 article-title: Galectin-3 marks activated macrophages in failure-prone hypertophied hearts and contributes to cardiac dysfunction publication-title: Circulation doi: 10.1161/01.CIR.0000147181.65298.4D contributor: fullname: Sharma – volume: 23 start-page: 4612 year: 2017 ident: 10.1016/j.conctc.2019.100500_bib15 article-title: Association of serum galectin-3 with acute exacerbation of chronic obstructive pulmonary disease publication-title: Med. Sci. Monit. doi: 10.12659/MSM.903472 contributor: fullname: Feng – volume: 230 start-page: 160 year: 2009 ident: 10.1016/j.conctc.2019.100500_bib9 article-title: The regulation of inflammation by galectin-3 publication-title: Immunol. Rev. doi: 10.1111/j.1600-065X.2009.00794.x contributor: fullname: Henderson – volume: 66 start-page: 1599 year: 2007 ident: 10.1016/j.conctc.2019.100500_bib1 article-title: Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2006.067470 contributor: fullname: Hill – volume: 13 year: 2018 ident: 10.1016/j.conctc.2019.100500_bib16 article-title: The therapeutic potential of blocking galectin-3 expression in acute myocardial infarction and mitigating inflammation of infarct region: a clinical outcome-based translational study publication-title: Biomark. Insights doi: 10.1177/1177271918771969 contributor: fullname: Mosleh – volume: 16 start-page: 595 year: 2004 ident: 10.1016/j.conctc.2019.100500_bib11 article-title: Galectin-3 in osteoarthritis: when the fountain of youth doesn't deliver its promises publication-title: Curr. Opin. Rheumatol. doi: 10.1097/01.bor.0000129663.76107.d6 contributor: fullname: Reboul – volume: 48 start-page: 2788 year: 2003 ident: 10.1016/j.conctc.2019.100500_bib14 article-title: Galectin 3 and its binding protein in rheumatoid arthritis publication-title: Arthritis Rheum. doi: 10.1002/art.11287 contributor: fullname: Ohshima – volume: 5 start-page: 77 year: 2013 ident: 10.1016/j.conctc.2019.100500_bib5 article-title: Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations publication-title: Ther Adv Musculoskelet Dis doi: 10.1177/1759720X12467868 contributor: fullname: Sokolove – volume: 22 start-page: 363 year: 2014 ident: 10.1016/j.conctc.2019.100500_bib6 article-title: OARSI guidelines for the non-surgical management of knee osteoarthritis publication-title: Osteoarthr. Cartil. doi: 10.1016/j.joca.2014.01.003 contributor: fullname: McAlindon – volume: 70 start-page: 323 year: 2015 ident: 10.1016/j.conctc.2019.100500_bib8 article-title: Galectin-3 in heart failure pathology--"another brick in the wall"? publication-title: Acta Cardiol. doi: 10.1080/AC.70.3.3080637 contributor: fullname: Lala – volume: 4 year: 2018 ident: 10.1016/j.conctc.2019.100500_bib13 article-title: Patient-reported outcome measures in osteoarthritis: a systematic search and review of their use and psychometric properties publication-title: RMD Open doi: 10.1136/rmdopen-2018-000715 contributor: fullname: Lundgren-Nilsson – volume: 1855 start-page: 235 year: 2015 ident: 10.1016/j.conctc.2019.100500_bib10 article-title: Galectin expression in cancer diagnosis and prognosis: a systematic review publication-title: Biochim. Biophys. Acta contributor: fullname: Thijssen – volume: 6 year: 2011 ident: 10.1016/j.conctc.2019.100500_bib12 article-title: Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury publication-title: PLoS One doi: 10.1371/journal.pone.0018683 contributor: fullname: Kolatsi-Joannou – volume: 27 start-page: 71 year: 2019 ident: 10.1016/j.conctc.2019.100500_bib2 article-title: Exploring longitudinal associations of histologically assessed inflammation with symptoms and radiographic damage in knee osteoarthritis: combined results of three prospective cohort studies publication-title: Osteoarthr. Cartil. doi: 10.1016/j.joca.2018.10.014 contributor: fullname: Mineten
SSID	ssj0001637125
Score	2.1995363
Snippet	This pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering from knee... OBJECTIVEThis pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering... Objective: This pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients...
SourceID	doaj pubmedcentral proquest crossref pubmed elsevier
SourceType	Open Website Open Access Repository Aggregation Database Index Database Publisher
StartPage	100500
SubjectTerms	Galectin-3 Modified citrus pectin Osteoarthritis
SummonAdditionalLinks	– databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELaAA-JSteXRpS0KUq8WfsWPI7S7cGkvBak3y7EdsRyyiGX_PzNOstqlBy5cEyeOv3E8D898JuRHyLmGaaSoEKahSjSMusQi5SGJxFptRcB655u_5s8_-2uKNDnro74wJ6ynB-6Bu4itTVEGnqyJyoEzwVQLfrq2gWcBnZTVl9kNZ6pEV7Q0vJy4KlTNqdW1GuvmSnIX-JqxMBhyh3kCNRa4beilQt-_pZ7-Nz9fZ1FuqKXZR_JhsCery34cn8hO7j6T_d_DjvkhubwCbYXh8ApW4aeAcXpMPK2uA8br5x2V1byrBnbVZYVh2QrrPhaAzH0hPDoid7Pp7c8bOhybQGMt3DPlxqaWt4WrKwFYWKchwFFpmyaYaBJGLnQNbpfJwUWmYnYth7agu3OOQctjstctuvyFVLVhQaaEBdZSOds0kqFBkOtgo1aaTQgdQfOPPTuGH9PGHnwPskeQfQ_yhFwhsuu2yG1dLoDE_SBx_5bEJ8SMcvGDmdCrf3jV_I3uz0cxeviLEPLQ5cVq6YUEVS6lUmJCTnqxrj8SVj1kOIKnzZbAt0axfaeb3xembu2YAxvp9D2G_ZUcCPT1S_7bN7L3_LTK38nuMq3Oytx_AbtXBQ8 priority: 102 providerName: Directory of Open Access Journals
Title	Blocking extracellular Galectin-3 in patients with osteoarthritis
URI	https://dx.doi.org/10.1016/j.conctc.2019.100500 https://www.ncbi.nlm.nih.gov/pubmed/31872160 https://search.proquest.com/docview/2330333442 https://pubmed.ncbi.nlm.nih.gov/PMC6909224 https://doaj.org/article/cf8dc3a1d87c4944804f39068a1e2054
Volume	17
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB11OVS9VP0AuoWiVOJq1rGdOD4ChXKhqlSQuFmO7ZRUJYt22f_fGSdBpBwq9ZrvzEzyZiZvXgAOXYwFhpFiQuiaKVFzZgL3LHdBBN6UlXA073zxQ3-7qb6ckUxOMc7CJNK-r9uj7vfdUdfeJm7l_Z1fjDyxxffLU6zoDELPYgYzzA2flOipsVJKjag9jsklLheWlj4JFuaGaAEFpx_AYTSTcg2fIFIS7p8A0_PE82_-5BNAOn8Dr4dMMjvur_gtvIjdO3h5OXwrfw_HJ4hT1AjP8P27ctShJ8pp9tVRp77tmMzaLht0VdcZNWQzmvhYog1uk9TRNlyfn12dXrDhhwnMF8I8sFxXocmbpNIVVCNpQkNgidLUtdNeB-pZlAUWXDo647ny0TQ5bouoHaN3pdyBrW7ZxQ-QFZo7GQKNVktlqrqWnFKBWLjKl6rkc2Cj0ex9r4thR8LYL9vb25K9bW_vOZyQZR-3JVXrtGC5-mkH31rfVMFLl4dKe2WwcOR4E4aXlcujwICagx79YocEoQd-PFT7j9N_Ht1o8fkhk7suLjdrKySCuJRKiTns9m59vMgxQvC8E4dP7mK6BkM2aXQPIfrxv_fcg1eCSvtEd9uHrYfVJn6C2TpsDlLf4CBF_R_x9AU7
link.rule.ids	230,315,729,782,786,866,887,2108,27935,27936,53803,53805
linkProvider	National Library of Medicine
linkToHtml	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7RVoJeoLzKAoUgcU3XsZ04PralZRHdCokicbMc26FBNFvtdv8_M05SNXCo1GvsxLFnnHnkm88AH20IOaqRTDlXVSp5xVLtmUsz67lndVFyS_XOs-_q7Gf56ZhocvKhFiaC9l3V7Ld_Lvfb5iJiK68u3XTAiU2_zY8wotNoeqYbsIX7lYlbQXpMrRRCod0eCuUimguDSxcpCzNNwICc0RFwqM_EXcNGNilS949M0_-u578Iylsm6eTJPSezA497HzQ56JqfwoPQPoOH8_4v-3M4OEQLRyn0BL_cS0u5fQKrJp8t5fibNhVJ0yY9I-sqoVRuQrUiCxzwIpIkvYAfJ8fnR7O0P2ohdTnX12mmSl9ndeT38rIWVNvBMbipq8oqpzxlO4ocQzUVrHZMuqDrDPuivQ_B2UK8hM120YZXkOSKWeE9FWULqcuqEoyciJDb0hWyYBNIh8U2Vx2jhhmgZr9NJydDcjKdnCZwSBK56Ut82PHCYvnL9AtpXF16J2zmS-WkxpCT4SQ0K0qbBY6qOAE1yNP0rkXnMuCjmjuG_zCI3-DOoyW3bVisV4YLNP9CSMknsNupw81LDpqF444UZTSLcQvqR2T37vXh9b3vfA-PZufzU3P65ezrG9jmlCCIoLm3sHm9XIc92Fj59bu4Z_4C4RMZ0Q
linkToPdf	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JbtswEB00KRD00n1xVxXolTFFSqJ4zOamaBMEaAv0RlAk1ShIZMOO_78zlGRE6SFAe7Vp0-Q8eha9eQT4ZEPIEUYZE0JVLBMVZ9pzx1Lrhed1UQpL_c7H39Xpr_LwiGRyNld9RdK-q5rd9vJqt23OI7dyceWmA09senZygBmdRtczXfh6ugX38czy_EaiHssrhVTou4dmucjowgTTRdnCVBM5IOd0DRximvRr-MgvRfn-kXv6O_y8zaK84ZZmj_5jQY_hYR-LJnvdkCdwL7RPYeekf9r-DPb20dNRKT3Bf_ClpRo_kVaTz5Zq_U3LZNK0Sa_MukqopJtQz8gcJz2PYknP4efs6MfBMeuvXGAuF_qapar0dVpHnS-f1ZJ6PAQmOXVVWeWUp6pHkWPKpoLVjmcu6DrFsej3Q3C2kC9gu5234RUkueJWek_N2TLTZVVJTsFEyG3piqzgE2DDhptFp6xhBsrZhelsZchWprPVBPbJKpuxpIsdX5gvf5t-M42rS--kTX2pXKYx9eS4CM2L0qZBICQnoAabmj7E6EIH_Krmjuk_DhAweAJpy20b5uuVERLDACmzTEzgZQeJzY8c0IXzjsAyWsX4HcRIVPnuMfH6nz_5AXbODmfm25fTr2_ggaA6QeTOvYXt6-U6vIOtlV-_j8fmD8W4HFE
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Blocking+extracellular+Galectin-3+in+patients+with+osteoarthritis&rft.jtitle=Contemporary+clinical+trials+communications&rft.au=Andrews%2C+Alec+R.&rft.au=Fernandes%2C+Ana+D.&rft.au=Brownmiller%2C+Seth+E.&rft.au=Hanna%2C+Yousif&rft.date=2020-03-01&rft.pub=Elsevier+Inc&rft.issn=2451-8654&rft.eissn=2451-8654&rft.volume=17&rft_id=info:doi/10.1016%2Fj.conctc.2019.100500&rft.externalDocID=S2451865419302637
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2451-8654&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2451-8654&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2451-8654&client=summon